RPS19 and ovarian cancer: We also uncovered some novel interactions that have not been reported in ccRCC, for example, the ligand–receptor interaction between ribosomal protein S19 (RPS19) and complement C5a receptor 1 (C5AR1), which has been shown to contribute to immunosuppression in the human breast and ovarian cancer TME73.